Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized non-inferiority trial of two HIV post-exposure prophylaxis regimens
ChiCTR1900027321Phase 4Not yet recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide, lamivudine and 2 more in human immunodeficiency virus infection (HIV) (2 arms), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: HIV antibody positive rate. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
elvitegravircobicistatemtricitabinetenofovir alafenamidelamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR1900027321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027321.